In a report issued on February 7, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Concert Pharma (CNCE), with a price target of $25.00. The company’s shares closed last Monday at $11.12.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 13.3% and a 49.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Concert Pharma with a $24.00 average price target, which is a 108.3% upside from current levels. In a report issued on January 23, Janney Montgomery also maintained a Buy rating on the stock with a $22.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.83 and a one-year low of $5.36. Currently, Concert Pharma has an average volume of 201.6K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CNCE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders.
